Skip to main content
. 2017 Feb 1;3(1):39–56. doi: 10.1159/000452341

Table 7.

Studies concerning the use of botulinum toxin type A (BoNT-A) injection therapy in Raynaud disease and phenomenon

First author [Ref.], year Type of study n BoNT-A doses/hand Follow-up Retreatment Results
Motegi [93], 2016 Prospective, case series 10 10 U/finger 16 weeks No Improved (pain, DU, skin temperature)

Uppal [94], 2014 Prospective 20 100 U 6 months No Improved (pain with VAS, DU)

Jenkins [91], 2013 RCT pilot; doubleblind; placebo 8 40 U No Increase in digital pulp temperature

Smith [95], 2012 Case report 1 100 U No Patient reported improvement in pain and DU

Neumeister [96], 2010
Neumeister [90], 2009
Retrospective case series 33 50 U 1 – 6 years Yes (21%) 100% of DU healed, relief in 85% of patients

Fregene [92], 2009 Retrospective case series 26 20 ' 100 U 18 months Yes (20%) 48% of DU healed, 35% pain reduction (VAS)

Kossintseva [97], 2008 Case report 1 100 U 12 months No Pain decreased, DU not reported

Van Beek [89], 2007 Retrospective case series 11 50 ' 200 U 9.6 months Yes (45%) 100% decrease in pain (VAS), 82% of DU healed

Sycha [88], 2004 Pilot to RCT, case report 2 12 ' 300 U No 37% pain reduced in 1 patient (VAS), other unknown

RCT, randomized controlled trial; DU, digital ulcer; VAS, Visual Analogue Scale.